Identification

Generic Name
1-benzylimidazole
DrugBank Accession Number
DB04581
Background

1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 158.1998
Monoisotopic: 158.08439833
Chemical Formula
C10H10N2
Synonyms
  • 1-benzyl-1H-imidazole

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGlutaminyl-peptide cyclotransferaseNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Acebutolol1-benzylimidazole may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 1-benzylimidazole.
AlclofenacThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Alclofenac.
AlfentanilThe risk or severity of hypertension can be increased when Alfentanil is combined with 1-benzylimidazole.
Alfuzosin1-benzylimidazole may increase the hypotensive activities of Alfuzosin.
Aliskiren1-benzylimidazole may decrease the antihypertensive activities of Aliskiren.
AlmotriptanThe risk or severity of hypertension can be increased when Almotriptan is combined with 1-benzylimidazole.
Ambrisentan1-benzylimidazole may decrease the antihypertensive activities of Ambrisentan.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
N-substituted imidazoles
Alternative Parents
Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / N-substituted imidazole / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
W4C9Z5BCV7
CAS number
4238-71-5
InChI Key
KKKDZZRICRFGSD-UHFFFAOYSA-N
InChI
InChI=1S/C10H10N2/c1-2-4-10(5-3-1)8-12-7-6-11-9-12/h1-7,9H,8H2
IUPAC Name
1-benzyl-1H-imidazole
SMILES
C(N1C=CN=C1)C1=CC=CC=C1

References

Synthesis Reference

Natsuo Sawa, Takeshi Masuda, Shozo Miura, Naoki Kano, Kazuo Kamagata, Masayuki Ito, "Process for preparation of 1-benzylimidazole compound." U.S. Patent US5021584, issued June 04, 1991.

US5021584
General References
  1. Mori Y, Iimura K, Hirano K: N-benzylimidazole, a potent inducer of rat liver enzymes involved in mutagenic activation of various carcinogens. Mutat Res. 1993 Jun;302(2):129-33. [Article]
  2. Lucas J, Chan PS, Mateja N, Cervoni P, Ronsberg MA, Lipchuck LM: 1-Benzylimidazole, a thromboxane synthetase inhibitor acutely lowers blood pressure mainly by alpha-adrenoceptor blockade in spontaneously hypertensive rats (SHR). Prostaglandins Leukot Med. 1983 Dec;12(4):409-21. [Article]
  3. Tuttle RS, Garcia-Minor C, Simon M: Cardiovascular effects of 1-benzylimidazole. J Pharmacol Exp Ther. 1975 Sep;194(3):624-32. [Article]
PubChem Compound
77918
PubChem Substance
46506844
ChemSpider
70309
BindingDB
7887
ChEMBL
CHEMBL14192
ZINC
ZINC000000169811
PDBe Ligand
1BN
PDB Entries
2afx / 3pb9 / 5s8m / 7d1d
MSDS
Download (69.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)68-70 °CPhysProp
boiling point (°C)310 °CPhysProp
logP1.60AVDEEF,A (1993)
pKa6.7AVDEEF,A (1993)
Predicted Properties
PropertyValueSource
Water Solubility1.47 mg/mLALOGPS
logP1.58ALOGPS
logP1.8ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)6.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.82 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity48.52 m3·mol-1ChemAxon
Polarizability17.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9565
Blood Brain Barrier+0.983
Caco-2 permeable+0.6674
P-glycoprotein substrateNon-substrate0.7264
P-glycoprotein inhibitor INon-inhibitor0.9772
P-glycoprotein inhibitor IINon-inhibitor0.9044
Renal organic cation transporterInhibitor0.5285
CYP450 2C9 substrateNon-substrate0.8583
CYP450 2D6 substrateNon-substrate0.8724
CYP450 3A4 substrateNon-substrate0.8169
CYP450 1A2 substrateInhibitor0.7491
CYP450 2C9 inhibitorNon-inhibitor0.7615
CYP450 2D6 inhibitorInhibitor0.5463
CYP450 2C19 inhibitorNon-inhibitor0.5434
CYP450 3A4 inhibitorNon-inhibitor0.6991
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8173
Ames testAMES toxic0.836
CarcinogenicityNon-carcinogens0.9052
BiodegradationNot ready biodegradable0.7719
Rat acute toxicity2.4931 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8224
hERG inhibition (predictor II)Non-inhibitor0.8281
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.94 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-9500000021-54b882fcb3841d682e6b

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length a...
Gene Name
QPCT
Uniprot ID
Q16769
Uniprot Name
Glutaminyl-peptide cyclotransferase
Molecular Weight
40876.14 Da

Drug created at September 11, 2007 17:48 / Updated at June 12, 2020 16:52